A Medical Device Daily
Medrad (Warrendale, Pennsylvania) reported that it has signed a distribution and co-marketing partnership agreement with Petnet Solutions, a subsidiary of Siemens Medical Solutions (Hoffman Estates, Illinois). The agreement will enable healthcare providers to inject fluorodeoxyglucose (FDG) for positron emission tomography/computed tomography (PET/CT) imaging procedures in an innovative way.
The partnership will leverage Medrad's soon-to-be introduced PET infusion system and multi-dose FDG packaging and delivery from Petnet Solutions. PET/CT Imaging has proven effective in diagnosing and staging certain forms of cancer.
Medrad's PET infusion system, to be called Intego, is designed to automatically extract a patient dose from a multi-dose vial and deliver it directly to the patient. The system is mobile and includes dosimetry, shielding and a touch-screen interface.
Petnet Solutions has agreed to provide FDG to customers throughout its extensive, cyclotron-based radiopharmacy network in multi-dose vials and specially designed vial shields, which will allow for easy integration with Medrad's new system.
Michael Reitermann, CEO, molecular imaging at Siemens, said, "In addition to our traditional delivery method, by providing FDG in multi-dose vials compatible with the Medrad PET infusion system across our extensive network, we have the opportunity to help improve the way FDG is being handled and delivered."
Alan Connor, director of global marketing for Medrad Molecular Imaging, said, "We are very pleased that Petnet Solutions is the first FDG provider to agree to provide FDG in a manner compatible with the Intego System across its entire network. From the beginning of this project, Petnet Solutions has been instrumental to the development of this system and is dedicated to providing the latest in safety and clinical performance to [its] customers."
In other agreement news, Healthnostics (New York) is leveraging its relationship with Global Medical Direct (GMD; Lenexa, Kansas) to expand GMD's position in the growing diabetes supply market. Healthnostics and GMD report that because the diabetic supply market is portioned into mostly small- and medium-sized companies, the opportunities for GMD's growth and consolidation opportunities abound.
GMD said it is positioned to take full advantage of the growing demand for accessible and well-priced diabetic products and supplies, and expects with such an expanding market to increase revenues in the next fiscal year beginning July 1.
GMD supplies products and drugs used by diabetic patients to maintain control of the disease.